The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 336:434-436 February 6, 1997 Number 6
NextNext

Thrombopoietin — Clinically Realized?

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
For approximately 30 years, hematologists have sought the humoral regulator of platelet production, thrombopoietin.1 Although a factor with the appropriate physiologic effects was partially purified, the goal continued to evade researchers until 1994, when three laboratories simultaneously reported that c-Mpl ligand had the characteristics of thrombopoietin.2 Synonyms for thrombopoietin in the literature are c-Mpl ligand, mpl ligand, megapoietin, and megakaryocyte growth and development factor (a truncated version of thrombopoietin).

What explains the fact that thrombopoietin was ultimately purified and characterized by five laboratories almost simultaneously? In 1992, Wendling and colleagues described the c-mpl gene, the cellular homologue of v-. . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.